论文部分内容阅读
作者对照研究了小剂量人类重组红细胞生成素(r-HuEPO),经皮下注射(SC)或静脉注射(IV)两种不同途径,对慢性肾功能不全,血透病人之疗效。接受定期血透的慢性肾衰患者12例,其中肾小球肾炎6例,返流性肾病4例,SLE及肾血管疾患各1例,分为A、B两组。A组:rHuEPO 25U/kg 3次/周,Ⅳ;B组:25U/kg 2次/周SC。7周后剂量加倍,持续到14周。结果表明在第7,14周末,A组Hb(g/dl)增加1.1±0.4,2.8±0,5;B组为0.8±0.3,2.6±0.6。两组Hb上升程度无显著差异。 5例原先铁蛋白浓度<500μg/l者,r-HuEPO
The authors compared the effects of low-dose human recombinant erythropoietin (r-HuEPO), subcutaneous (SC) or intravenous (IV) administration on patients with chronic renal insufficiency and hemodialysis. Twelve patients with chronic renal failure who received regular hemodialysis included 6 glomerulonephritis, 4 reflux disease, 1 SLE and 1 renal disease, divided into A and B groups. Group A: rHuEPO 25U / kg 3 times / week, Ⅳ; Group B: 25U / kg 2 times / week SC. Dose doubled after 7 weeks until 14 weeks. The results showed that at the end of the 7th and 14th week, the Hb (g / dl) in group A increased by 1.1 ± 0.4,2.8 ± 0,5 and that in group B was 0.8 ± 0.3,2.6 ± 0.6. No significant difference in Hb rise between the two groups. 5 cases of the original ferritin concentration <500μg / l, r-HuEPO